Physician profile
Idil Baysal
NPI 1891434031
$8,223.44
in general payments reported to CMS, 2019-2025
14 companies · $2,912 in 2025
The $2,912 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,009 · 2023: $1,612 · 2024: $1,691 · 2025: $2,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,678 · Travel and Lodging: $1,349 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,678.14 |
| Travel and Lodging | $1,349.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,187.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,030.12 | 2022-2025 | Vercise, General - Dbs, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $3,616.97 | 2022-2025 | Synchromedii, Percept Pc Brainsense, Sensight |
| Cala Health, INC. | $122.97 | 2025 | Cala Kiq |
| Merz Pharmaceuticals, LLC | $91.29 | 2025 | Inbrija, Xeomin |
| Tg Therapeutics, INC. | $66.10 | 2025 | |
| Abbvie INC. | $58.97 | 2022-2025 | |
| Eisai INC. | $48.68 | 2025 | |
| Piramal Critical Care | $35.49 | 2024-2025 | |
| Csl Behring | $33.53 | 2025 | Hizentra |
| Alnylam Pharmaceuticals INC. | $29.71 | 2025 | Amvuttra |
| Ucb, INC. | $28.80 | 2025 | Nayzilam |
| Teva Pharmaceuticals USA, INC. | $22.84 | 2025 | Austedo Xr |
| Ipsen Biopharmaceuticals, INC | $21.53 | 2025 | Dysport |
| Lundbeck LLC | $16.44 | 2025 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Idil Baysal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.